Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
Open Access
- 17 February 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 18 (4), 446-453
- https://doi.org/10.1016/s1470-2045(17)30104-3
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Human papillomavirus type distribution in anal cancer and anal intraepithelial lesionsInternational Journal of Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Predictors and Patterns of Recurrence After Definitive Chemoradiation for Anal CancerInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Anal Cancer: Current and Future MethodologyCancer Investigation, 2006
- Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6Cancer Research, 2004
- Recapitulation of the Effects of the Human Papillomavirus Type 16 E7 Oncogene on Mouse Epithelium by Somatic Rb Deletion and Detection of pRb-Independent Effects of E7 In VivoMolecular and Cellular Biology, 2003
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000
- Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53Science, 1990